csfre: Recommended Scope for NPS Testing in the United States (Q2 – 2024)

The objective of this report is to provide updated guidance in developing an appropriate analytical scope of testing for novel psychoactive substances (NPS) in the United States (and around the world) based on current trends and intelligence.
This report is based on information available in Q1 2024 and early Q2 2024 and is subject to change along with the drug market.

Loader Loading...
EAD Logo Taking too long?
Reload Reload document
| Open Open in new tab

National Association of Drug Diversion Investigators Federal Tax ID: 52-1660752 / DUNS Number: 073539913

Copyright © 2024 - NADDI. All Rights Reserved. Privacy Policy / Trademark Policy / Copyright Policy / Refund Policy

Log in with your credentials

or    

Forgot your details?

Create Account